Navigation Links
A Genetic Approach For Crohn's And Colitis Disease Is Financed By The Jeffrey Epstein VI Foundation
Date:7/3/2012

NEY YORK, July 3, 2012  /PRNewswire/ -- The Jeffrey Epstein VI Foundation, which actively supports science research, has given substantial support to the Crohn's and Colitis Foundation of America to continue its Genetic Initiative to find a cure for the diseases.

Crohn's is a chronic inflammatory condition of the gastrointestinal tract. Every year, about 700,000 Americans are diagnosed, the majority being between the ages of 15 and 35. Crohn's affects the end of the small bowel, or ileum, the beginning of the colon and parts of the gastrointestinal tract. Ulcerative colitis affects the colon or large intestine.

The cause of Crohn's and Colitis is uncertain but the chronic inflammation stems from the immune system attacking microbial antigens in the gastrointestinal tract. Because of this, the disease is classified as an autoimmune disorder.

What is certain however is that Crohn's has a strong genetic component. Siblings are 30 times more likely to develop Crohn's than the general population. Children of those affected, are 3 to 20 times more likely to develop the disease and twins show a concordance of over 55%.

The Genetic Initiative at the Crohn's and Colitis Foundation of America, which recently received funding from The Jeffrey Epstein VI Foundation, is by far the most comprehensive effort of its kind to isolate the mutated genes that lead to the disease. The Initiative employs a dream team of specialists from different fields to identify genetic mutations and the chain of subsequent pathologies that cause Crohn's and Colitis. The Initiative is headed by Dr. Ramnik Xavier, Chairman of the Department of Gastroenterology at Massachusetts General Hospital in Boston. Xavier's laboratory has identified the largest number of genes associated with Crohn's to date. He is also a founding member of the Center for Computational and Integrative
'/>"/>

SOURCE www.jeffreyepstein.org
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. First Genetic Cure For Cancer Anchors Provocative New Thriller
2. Applied Genetics Initiates Commercial Operation
3. BioRealm to Develop Universal Genetic Screening Tool for Tobacco Addiction and Treatment
4. U.S. Senate Urged to Increase Federal Funding for Research into Hereditary Angioedema, a Rare and Serious Genetic Disorder
5. Study suggests expanding the genetic alphabet may be easier than previously thought
6. Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools
7. JS Genetics announces launch of XCAT-KS, a bloodless, cheek swab test for the diagnosis of Klinefelter syndrome and other Male sex chromosome aneuploidies
8. Global Genetic Engineering Industry
9. Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrigs Disease)
10. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
11. Khan Academy and 23andMe Partner to Promote Genetics Education on DNA Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   Senomyx , Inc. (NASDAQ: SNMX ... to discover, develop, and commercialize novel flavor ingredients for ... financial results for the second quarter 2015. ... remain on track to achieve our commercial and financial ... of the Company. "Since our last quarterly earnings report, ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... Reportlinker.com announces that a new ... its catalogue: DNA ... Purchase Plans and The Impact of ... http://www.reportlinker.com/p0681348/DNA-Microarray-Market-Trends-Installed-Base-Applications-Purchase-Plans-and-The-Impact-of-Next-Gen-Sequencing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic DNA ...
... Novartis announced today new pivotal Phase III data showing ... (SJIA) were able to substantially reduce their use of ... of commencing treatment with ACZ885 (canakinumab) (p<0.0001)[1]. ... primary endpoints, will be presented on November 9th at ...
... Jennerex, Inc., a private clinical-stage biotherapeutics company focused ... oncolytic products for cancer, today presented final data from ... in patients with advanced liver cancer showing a statistically ... dose group versus the low dose group.  The final ...
Cached Biology Technology:DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 2DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 3DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 4DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 5DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 6DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 7DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 8DNA Microarray Market Trends (Installed Base, Applications, Purchase Plans and the Impact of Next-Gen Sequencing) 9Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 2Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 3Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 4Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 5Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 6Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 7Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 2Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 3Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 4Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 5Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 6
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... VIB and Ghent University, both in Flanders, Belgium, is ... worth 750 000 euro. The Krber Foundation annually awards ... Friml gets the prize for his research into the ... the genetic, molecular and cellular processes that direct the ...
... have discovered components of the bovine mastitis-causing bacterium, Streptococcus ... This discovery could lead the way to finally developing a ... nearly 200M per year, requires the large scale use of ... A solution to this problem will be an important contribution ...
... the world,s largest living reptile - the estuarine crocodile - ... by huge stretches of ocean despite being a poor swimmer ... ecologists. Publishing their new study in the British Ecological Society,s ... a surfer catching a wave, the crocodiles ride ocean currents ...
Cached Biology News:VIB-UGent scientist Jiri Friml receives Koerber European Science Award 2010 2New discovery could aid development of elusive bovine mastitis vaccine 2Crocodiles ride ocean currents for ocean travel 2Crocodiles ride ocean currents for ocean travel 3
... silencing experiments often call for critical, ... Transfection Agent refines siRNA transfection protocols ... lipid-based formulation can be used to ... are subcultured without increased cytotoxicity. ...
... The CHEMICON® CaspaTag™ Pan-Caspase In Situ ... detection of active caspases in cells undergoing ... only. Not for use in diagnostic or ... Assay Kits use a novel approach to ...
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
... Cell and Tissue Staining Kits are intended ... range of histological and cytological specimens. These ... antibodies manufactured by either R&D Systems or ... on the formation of the Avidin-Biotin Complex ...
Biology Products: